Qiming Venture Partners USA — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations.
BiotechDeep TechSouth San Francisco, US
Forbes Huang(Co-Founder, Chief Operating Officer & Chief Business Officer)inGreg Lazar(Co-Founder & Chief Scientific Officer)inRichard Murray(Executive Officer, Director)Karim Dabbagh(Chief Executive Officer, Board Member)in
BoardAlicia Levey(Director)Michael Ross(Director)
Co-investorsQiming Venture PartnersSV Health InvestorsVersant VenturesAlexandriaDementia Discovery FundQiming Healthcare
Renasant Bio is a biopharmaceutical company developing oral small molecule corrector and potentiator therapies to restore the function of polycystin 1 and 2 proteins in autosomal dominant polycystic kidney disease (ADPKD).
BiotechHealthtechBerkeley, US
Jeremy Reiter(Scientific Co-Founder)Markus Delling(Scientific Co-Founder)Thomas Gustafson(Executive Officer)inEmily Conley(Executive Officer, Director)in
BoardEvan Caplan(Director)inCharlotte McKee(Director)
Co-investors5AM VenturesOrbiMedAtlas Venture
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.